CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SFXN2 (ImmuneEditome ID:118980)

1. Gene summary of enriched editing regions for SFXN2

check button Gene summary
Gene informationGene symbol

SFXN2

Gene ID

118980

GeneSynonymsSLC56A2
GeneCytomap

10q24.32

GeneTypeprotein-coding
GeneDescriptionsideroflexin-2
GeneModificationdate20230518
UniprotIDQ96NB2;A0A0C4DGR6;A0A1B0GX61;R4GMR9;R4GNC2;R4GMS6;R4GN63;R4GN74;R4GMW0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr10:102736308-102738173:+ENST00000369893.8ENSG00000156398.11SFXN2exonicAluSc5,G-rich,(AATA)n,AluSq,AluSpchr10:102736308-102738173:+.alignment
chr10:102739608-102741593:+ENST00000369893.8ENSG00000156398.11SFXN2UTR3MER5A,L1MB7,AluSx,AluJbchr10:102739608-102741593:+.alignment


Top

2. Tumor-specific enriched editing regions for SFXN2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000156398.11,SFXN2KIRCEAG5.1175e-03image
ENSG00000156398.11,SFXN2KIRPEAG1.9661e-02image
ENSG00000156398.11,SFXN2LIHCEAG1.7206e-02image
ENSG00000156398.11,SFXN2THCAEAG3.6961e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000156398.11,SFXN2KIRCPathEAG2.3309e-037.5757e-030.1333image
ENSG00000156398.11,SFXN2STADPathEAG5.2142e-031.2637e-02-0.1866image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr10:102739608-102741593:+STADEER4.8943e-021.8908e-026.0012e+03image

Top

3. Enriched editing regions and immune related genes for SFXN2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for SFXN2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000156398.11,SFXN2
KIRCEAGESENSG00000101782.10chr1823466168:23466276:23467398:23467526:23473428:23473483-0.23046.9157e-031.1675e-18-0.4817imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DIS3L2;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000268279.2chr314135216:14135232:14135806:141359080.20164.4320e-028.8394e-190.4825imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF2;UPF1;VIM;XRN2;ZC3H7B;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000119242.4chr12123943346:123943493:123944271:1239443640.19874.9169e-027.4580e-160.4450imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000015479.13chr5139310042:139315738:139316075:1393160930.19924.9310e-021.7736e-150.4391imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000144445.11chr2210027295:210027350:210028844:2100289690.22939.1439e-031.1927e-130.4154imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;RBM5;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;ZC3H7B;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_HEME_METABOLISM
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000151498.7chr11134257746:134259745:134261043:1342611790.22861.0655e-023.6078e-150.4347imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZC3H7B;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000110429.9chr1133740938:33742084:33747129:337473200.22231.2879e-023.5743e-180.4750imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000074410.9chr1563327148:63327233:63328097:633281240.22461.3566e-022.2300e-160.4529imageNADAR;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;DIS3L2;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FMR1;FUS;HNRNPA1;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28B;MOV10;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;SRSF1;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF2;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000171766.11chr1545361123:45362221:45363899:453640160.21891.7543e-025.9098e-130.4031imageNADAR;BUD13;CSTF2T;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPM;LIN28A;LIN28B;MBNL2;NOP58;PRPF8;RBFOX2;SF3A3;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1NAMonocytesGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
ENSG00000156398.11,SFXN2
KIRCEAGIRENSG00000119689.10chr1474891055:74891167:74892833:748929430.21991.8539e-022.4409e-150.4372imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZC3H7B;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS

More results



Top

5. Enriched editing regions and immune infiltration for SFXN2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000156398.11,SFXN2BLCAEAGNK_cells_resting1.5353e-020.2038image
chr10:102736308-102738173:+BRCAEERT_cells_follicular_helper1.5328e-030.1123image
chr10:102739608-102741593:+BRCAEERNeutrophils2.2265e-030.1990image
ENSG00000156398.11,SFXN2BRCAEAGNeutrophils9.7299e-030.0901image
ENSG00000156398.11,SFXN2CESCEAGNK_cells_resting3.6393e-020.2035image
ENSG00000156398.11,SFXN2COADEAGDendritic_cells_activated1.4782e-060.4247image
ENSG00000156398.11,SFXN2GBMEAGT_cells_follicular_helper4.4778e-020.2460image
ENSG00000156398.11,SFXN2HNSCEAGMacrophages_M06.7001e-030.2736image
ENSG00000156398.11,SFXN2KIRCEAGT_cells_regulatory_(Tregs)1.1721e-020.1458image
ENSG00000156398.11,SFXN2LGGEAGMacrophages_M22.8740e-02-0.1583image
ENSG00000156398.11,SFXN2LIHCEAGB_cells_memory1.3367e-020.1705image
chr10:102736308-102738173:+OVEERNeutrophils2.9262e-030.2249image
chr10:102739608-102741593:+OVEERMacrophages_M16.2634e-030.3013image
ENSG00000156398.11,SFXN2OVEAGPlasma_cells4.6298e-02-0.1414image
ENSG00000156398.11,SFXN2PAADEAGMacrophages_M04.7670e-020.2326image
ENSG00000156398.11,SFXN2PCPGEAGDendritic_cells_activated1.8460e-020.2938image
chr10:102739608-102741593:+PRADEERNK_cells_activated1.4657e-02-0.2511image
ENSG00000156398.11,SFXN2PRADEAGNK_cells_resting5.7536e-030.1268image
ENSG00000156398.11,SFXN2SKCMEAGMonocytes4.7191e-020.1481image
ENSG00000156398.11,SFXN2STADEAGB_cells_memory3.5371e-020.1532image
ENSG00000156398.11,SFXN2THCAEAGNK_cells_activated1.3185e-030.1691image


Top

6. Enriched editing regions and immune gene sets for SFXN2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000156398.11,SFXN2BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.1015e-02-0.1723image
chr10:102736308-102738173:+BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER6.9762e-04-0.1201image
chr10:102739608-102741593:+BRCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER4.6772e-020.1301image
ENSG00000156398.11,SFXN2BRCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.0443e-04-0.1349image
ENSG00000156398.11,SFXN2CESCGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.0610e-02-0.2473image
ENSG00000156398.11,SFXN2COADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.1196e-05-0.3907image
ENSG00000156398.11,SFXN2GBMGSVA_HALLMARK_COMPLEMENTEAG1.3326e-02-0.3010image
ENSG00000156398.11,SFXN2HNSCGSVA_HALLMARK_E2F_TARGETSEAG1.4657e-04-0.3761image
ENSG00000156398.11,SFXN2KIRCGSVA_HALLMARK_HEME_METABOLISMEAG1.6991e-06-0.2731image
ENSG00000156398.11,SFXN2KIRPGSVA_HALLMARK_PEROXISOMEEAG1.7996e-03-0.2391image
ENSG00000156398.11,SFXN2LAMLGSVA_HALLMARK_MYC_TARGETS_V2EAG2.1263e-04-0.4076image
chr10:102739608-102741593:+LAMLGSVA_HALLMARK_MYC_TARGETS_V2EER3.6091e-02-0.3002image
ENSG00000156398.11,SFXN2LGGGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.2046e-040.2576image
ENSG00000156398.11,SFXN2LIHCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.1625e-030.2226image
ENSG00000156398.11,SFXN2LUADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.2682e-04-0.2190image
ENSG00000156398.11,SFXN2LUSCGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG3.7419e-04-0.2645image
chr10:102736308-102738173:+OVGSVA_HALLMARK_MYC_TARGETS_V2EER8.3942e-030.1998image
chr10:102739608-102741593:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.3684e-040.3762image
ENSG00000156398.11,SFXN2PAADGSVA_HALLMARK_ANGIOGENESISEAG1.5975e-020.2812image
ENSG00000156398.11,SFXN2PCPGGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG4.2717e-02-0.2541image
ENSG00000156398.11,SFXN2PRADGSVA_HALLMARK_NOTCH_SIGNALINGEAG7.2625e-05-0.1814image
chr10:102739608-102741593:+PRADGSVA_HALLMARK_E2F_TARGETSEER1.5497e-020.2490image
ENSG00000156398.11,SFXN2SKCMGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.5121e-04-0.2697image
chr10:102739608-102741593:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7759e-030.4554image
ENSG00000156398.11,SFXN2STADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG5.7021e-04-0.2483image
ENSG00000156398.11,SFXN2THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG9.2265e-06-0.2320image
ENSG00000156398.11,SFXN2THYMGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG5.6355e-04-0.3865image
ENSG00000156398.11,SFXN2UCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.5319e-02-0.2773image
ENSG00000156398.11,SFXN2UVMGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.5339e-03-0.4790image


Top

7. Enriched editing regions and drugs for SFXN2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000156398.11,SFXN2BLCAEmbelinEAG4.6717e-050.3359image
chr10:102736308-102738173:+BRCABMS.708163EER1.1934e-030.1149image
ENSG00000156398.11,SFXN2BRCACCT007093EAG1.1627e-03-0.1131image
chr10:102739608-102741593:+BRCADocetaxelEER2.3592e-02-0.1480image
ENSG00000156398.11,SFXN2COADBexaroteneEAG4.3913e-040.3172image
ENSG00000156398.11,SFXN2ESCACisplatinEAG4.4246e-020.2270image
chr10:102739608-102741593:+ESCAABT.888EER2.0078e-03-0.6218image
ENSG00000156398.11,SFXN2GBMJNK.9LEAG3.2829e-030.3541image
ENSG00000156398.11,SFXN2HNSCMG.132EAG3.9455e-040.3527image
ENSG00000156398.11,SFXN2KICHBX.795EAG1.9358e-030.5197image
ENSG00000156398.11,SFXN2KIRCLapatinibEAG3.5258e-040.2060image
ENSG00000156398.11,SFXN2KIRPGW.441756EAG1.8499e-020.1816image
ENSG00000156398.11,SFXN2LAMLBMS.509744EAG3.0094e-030.3317image
chr10:102739608-102741593:+LAMLFH535EER1.6686e-020.3404image
ENSG00000156398.11,SFXN2LGGGemcitabineEAG2.5656e-050.2995image
ENSG00000156398.11,SFXN2LIHCBI.2536EAG6.0390e-070.3363image
ENSG00000156398.11,SFXN2LUADAG.014699EAG9.2215e-04-0.2063image
ENSG00000156398.11,SFXN2LUSCElesclomolEAG1.1779e-02-0.1889image
ENSG00000156398.11,SFXN2MESOMetforminEAG1.8461e-02-0.4141image
chr10:102736308-102738173:+OVAZD.0530EER7.2597e-030.2034image
ENSG00000156398.11,SFXN2OVMethotrexateEAG3.6080e-03-0.2059image
chr10:102739608-102741593:+OVAxitinibEER6.1277e-030.3021image
ENSG00000156398.11,SFXN2PAADAP.24534EAG2.1604e-02-0.2685image
chr10:102739608-102741593:+PRADCCT018159EER5.7677e-030.2827image
ENSG00000156398.11,SFXN2PRADAMG.706EAG9.0287e-06-0.2025image
ENSG00000156398.11,SFXN2SARCAICAREAG5.6441e-030.3166image
ENSG00000156398.11,SFXN2SKCMJNK.9LEAG2.8162e-030.2214image
chr10:102739608-102741593:+STADAKT.inhibitor.VIIIEER1.4116e-02-0.3805image
ENSG00000156398.11,SFXN2STADEHT.1864EAG2.8349e-02-0.1595image
ENSG00000156398.11,SFXN2THCAAxitinibEAG1.0203e-05-0.2309image
ENSG00000156398.11,SFXN2THYMAZD6244EAG2.8846e-05-0.4602image
ENSG00000156398.11,SFXN2UCECBX.795EAG2.8949e-040.4045image
ENSG00000156398.11,SFXN2UVMAZD6482EAG4.3429e-030.4364image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType